亿胜生物(01061.HK) 宣布,集团已与日本郡是医疗株式会社订立战略合作框架协议。这标志着双方拓展商业合作关系、建立全球合作平台以推进再生医学与创伤修复领域创新研发的重要里程碑。该协议以双方在中国内地现有的商业合作关系为基础,将合作版图拓展至东南亚的关键市场。协议同时约定,郡是医疗将开放其技术能力与产业资源,助力亿胜生物旗下碱性成纤维细胞生长因子(FGF-2)系列产品开拓日本市场;双方还将启动...
Source Link亿胜生物(01061.HK) 宣布,集团已与日本郡是医疗株式会社订立战略合作框架协议。这标志着双方拓展商业合作关系、建立全球合作平台以推进再生医学与创伤修复领域创新研发的重要里程碑。该协议以双方在中国内地现有的商业合作关系为基础,将合作版图拓展至东南亚的关键市场。协议同时约定,郡是医疗将开放其技术能力与产业资源,助力亿胜生物旗下碱性成纤维细胞生长因子(FGF-2)系列产品开拓日本市场;双方还将启动...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.